P-006

N/A

Report date: 2024/06/13 16:53:49
First In Class

Base Information

Drug NameP-006
Drug Alias Name23ME-00610P-00623ME’610
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionCell surface glycoprotein CD200 receptor 1 blockersOX-2 membrane glycoprotein blockersT lymphocytes stimulants +[4] 
TargetsCell surface glycoprotein CD200 receptor 1OX-2 membrane glycoprotein
Therapy Area/IndicationsSolid tumoursMicrosatellite instability-high cancerFallopian Tube Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator Companies23andme Inc
China Registration ClassN/A

Develop Information

Active Companies23andme Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursMicrosatellite instability-high cancerFallopian Tube Neoplasms +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A